Photo taken from Yale Cancer Center/X
Jun 6, 2024, 04:19
Roy Herbst shared the updated results from the COAST clinical trial – Yale Cancer Center
Yale Cancer Center shared a post on X:
“Roy Herbst shared the updated results from the COAST clinical trial, a phase 2 study of durvalumab with/without oleclumab or monalizumab in patients with stage 3 unresectable NSCLC.”
Source: Yale Cancer Center/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46
Nov 13, 2024, 15:32
Nov 13, 2024, 15:29
Nov 13, 2024, 15:25